I agree with you and the investment approach. 100% of GERN revenue comes from NIH SBIR which means: 1. Uncle Sam is paying for 30% of the research bill; 2. The innovation is impressive but still a basic research; 3. The research team is good; 4. The work is monitored by NIH, and is not hype. GERN is still a research company, and if indeed the work is successful, another team of management will come in to market the product. Why do everyone want the stock to double overnight? Give it time!